Literature DB >> 29680094

The Use of MCDA in HTA: Great Potential, but More Effort Needed.

Kevin D Marsh1, Mark Sculpher2, J Jaime Caro3, Tommi Tervonen4.   

Abstract

The potential for multi-criteria decision analysis (MCDA) to support health technology assessment (HTA) has been much discussed, and various HTA agencies are piloting or applying MCDA. Alongside these developments, good practice guidelines for the application of MCDA in health care have been developed. An assessment of current applications of MCDA to HTA in light of good practice guidelines reveals, however, that many have methodologic flaws that undermine their usefulness. Three challenges are considered: the use of additive models, a lack of connection between criteria scales and weights, and the use of MCDA in economic evaluation. More attention needs to be paid to MCDA good practice by researchers, journal editors, and decision makers and further methodologic developments are required if MCDA is to achieve its potential to support HTA.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  good practice; health technology assessment; multi-criteria decision analysis; reimbursement

Mesh:

Year:  2017        PMID: 29680094     DOI: 10.1016/j.jval.2017.10.001

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  18 in total

1.  Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off.

Authors:  Laura Panattoni; Charles E Phelps; Tracy A Lieu; Stacey Alexeeff; Suzanne O'Neill; Jeanne S Mandelblatt; Scott D Ramsey
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

2.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

3.  Could or Should We Use MCDA in the French HTA Process?

Authors:  Salah Ghabri; Jean-Michel Josselin; Benoît Le Maux
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

4.  Fostering Responsible Innovation in Health: An Evidence-Informed Assessment Tool for Innovation Stakeholders.

Authors:  Hudson P Silva; Andrée-Anne Lefebvre; Robson R Oliveira; Pascale Lehoux
Journal:  Int J Health Policy Manag       Date:  2021-03-14

Review 5.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

6.  Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Authors:  J Jaime Caro; John E Brazier; Jonathan Karnon; Peter Kolominsky-Rabas; Alistair J McGuire; Erik Nord; Michael Schlander
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

7.  A novel measure of drug benefit-risk assessment based on Scale Loss Score.

Authors:  Gaelle Saint-Hilary; Veronique Robert; Mauro Gasparini; Thomas Jaki; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2018-07-20       Impact factor: 3.021

8.  Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.

Authors:  Aris Angelis; Mark Thursz; Vlad Ratziu; Alastair O'Brien; Lawrence Serfaty; Ali Canbay; Ingolf Schiefke; Joao Bana E Costa; Pascal Lecomte; Panos Kanavos
Journal:  Med Decis Making       Date:  2020-08       Impact factor: 2.583

9.  Priority setting in health: development and application of a multi-criteria algorithm for the population of New Zealand's Waikato region.

Authors:  Rashmi Dayalu; Elizabeth T Cafiero-Fonseca; Victoria Y Fan; Heather Schofield; David E Bloom
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09

10.  Introduction: priority setting in global health.

Authors:  David E Bloom; Daniel Cadarette; Rashmi Dayalu; Jessica Sullivan
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.